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Abstract
Purpose: BRAF mutations are grouped in activating RAS-
independent signaling as monomers (class 1–V600E) or as
dimers (class 2–codons 597/601), and RAS-dependent with
impaired kinase activity (class 3–codons 594/596). Although
clinical, pathologic, and molecular features of V600EBRAF-
mutatedmetastatic colorectal cancer (mCRC) are well known,
limited data are available from the two other classes.
Experimental Design: Data from 117 patients with BRAF
(92 class 1, 12 class 2, and 13 class 3)-mutated mCRC were
collected. A total of 540 BRAF wt mCRCs were included as
control. IHC profiling was performed to determine the
consensus molecular subtypes (CMS), cytokeratin 7/20
profiles, tumor-infiltrating lymphocyte infiltration, and
BM1/BM2 categorization. Overall survival (OS) and pro-
gression-free survival were evaluated by Kaplan–Meier and
log-rank test.
Results: Class 3 BRAF-mutated mCRC was more frequently
left sided (P ¼ 0.0028), pN0 (P ¼ 0.0159), and without
peritoneal metastases (P ¼ 0.0176) compared with class 1,
whereas class 2 cases were similar to class 1. Hazard ratio for
OS, as compared with BRAF wt, was 2.38 [95% confidence
interval (CI), 1.61–3.54] for class 1, 1.90 (95%CI, 0.85–4.26)
for class 2, and 0.93 (95% CI, 0.51–1.69) for class 3
(P < 0.0001). Class 2 and 3 tumors were all assigned to
CMS2-3. A higher median CD3/CD8-positive lymphocyte
infiltration was observed in BRAF-mutated class 2 (P ¼
0.033) compared with class 3 cases.
Conclusions: For the first time, different clinical and path-
ologic features and outcome data were reported according to
the three BRAF mutation classes in mCRC. Specific targeted
treatment strategies should be identified in the near future for
such patients.
Introduction
Analysis of molecular alteration like RAS, V600EBRAFmutation,
andmicrosatellite instability are nowadays a consolidated routine
in the assessment of patients with metastatic colorectal cancer
(mCRC) (1) because all of them have a clear prognostic and/or
predictive role.
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Patients with V600EBRAF-mutated mCRC share specific clinical
and pathologic features, such as older age at diagnosis, female sex,
right sided location of primary tumors, poor differentiation,
mucinous histology, and microsatellite instability (2–4). In the
metastatic setting, V600EBRAF mutation occurs in approximately
10% of cases, and it is associated with poor prognosis and scarce
overall benefit from standard therapeutic approaches (5, 6).
Recently, specific gene expression profiles were described
for distinguishing two subgroups among V600EBRAF-mutated
cancers, named BM1 (showing activation of KRAS/mTOR/AKT/
4EBP1 pathway) and BM2 (with deregulation in the cell cycle;
ref. 7).
In recent years, thanks to the adoption of more accurate
techniques for mutational status evaluation such as next-
generation sequencing and mass spectrometry, other rare BRAF
mutations have been identified. Overall non-V600EBRAFmutations
occur in only 2% of patients with mCRC and cover 19 different
codons (8, 9). The clinical significance of these mutations is
largely unknown, due to the rarity of this condition.
Intriguing data on clinical features of non-V600EBRAF mutations
in patients with colorectal cancer emerged from two recent
retrospective cohort studies. Those reports agree in defining
the non-V600EBRAF-mutated population (mainly including muta-
tions in codons 594 and 596) as a distinct subgroup with its own
features, in particular longer overall survival (OS) compared with
V600EBRAF-mutated patients, no association with older age,
female sex, right sided tumor, mucinous histology, peritoneal
spread, and microsatellite instability (8, 10).
A deeper knowledge of non-V600EBRAF mutation derived from
functional studies on noncolorectal preclinical models, which
led to identify three classes of BRAF mutations: activating
RAS-independent BRAF mutations signaling as monomers (class
1) or as dimers (class 2) andRAS-dependentBRAFmutationswith
impaired kinase activity or kinase-dead (class 3; ref. 9). V600EBRAF
mutation belongs to class 1, whereas among non-V600EBRAF
mutations those affecting codons 601 and 597 are assigned to
class 2; while those in codons 594 and 596 to class 3. Preliminary
data, mainly derived from melanoma models, suggested also
a different sensitivity to BRAF inhibitors based on the three
classes (5, 9, 11).
Moving from all the above considerations, the simple distinc-
tion in V600E and non-V600E mutations may be too simplistic,
and a specific characterization of BRAF class 2 and 3 mutations
is needed.
This study aimed to provide a specific clinical, pathologic,




Patients were categorized as follows: (i) BRAF wild-type, (ii)
BRAF-mutant class 1 (i.e. harboring the V600E alteration), (iii)
BRAF-mutant class 2 (i.e. harboring codons 601 or 597 altera-
tions), and (iv) BRAF-mutant class 3 (i.e., harboring codons
594 or 596 alterations). For all the BRAF-mutated cases,
tissue specimens (paraffin embedded block or, as an alterna-
tive, 5-mm–thick slides for IHC analyses) of primary and/or
metastases were collected from the archives of the referral
Pathology Departments.
Data on availability of colorectal cancer samples diagnosed
with non-V600EBRAF mutations were firstly retrieved from the 9
Italian Surgical Pathology Units involved in the study. Clinical
and survival data of identified patients were retrieved from 8
Italian Oncology Units and matched with available molecular
and pathologic information. Main inclusion criteria were: diag-
nosis of metastatic colorectal cancer and available clinical data.
Clinicopathologic and survival data of V600EBRAF-mutated and
BRAF wild-type cases were collected from patients referred to the
Veneto Institute of Oncology, Padua, from January 2010 to
December 2016. Clinical and pathologic features are described
in Table 1. The study was approved by the Ethics Committee of
Veneto Institute of Oncology and was conducted according
to ethical standards laid down in the 1964 Declaration of
Helsinki and its later amendments. Written informed consent
was obtained from all the patients.
Mutational status analyses
RAS and BRAF mutational profiling were carried out on for-
malin-fixed paraffin-embedded (FFPE) samples from primary
tumors and/or pairedmetastases bymeans of Sanger Sequencing,
Sequenom MassArray technology (Myriapod Colon status,
Diatech Pharmacogenetics), or Ion Torrent PGM sequencing
(SiRe next-generation sequencing panel).
Pathologic evaluation and IHC analysis
Two experienced gastrointestinal pathologists, who were
blinded to mutational status and patients' outcome, revised
specific pathologic features of each sample.
Available primary and/or metastatic FFPE surgical samples
were processed using the Galileo CK3500 Arrayer, a semiauto-
matic and computer-assisted tissuemicroarray platform. Four and
three tissue cores (1 mm in diameter) were obtained from each
primary andmetastatic lesion, respectively. Small biopsy samples
were processed separately. IHC stainings were automatically
performed using the Bond Polymer Refine Detection kit
(Leica Biosystems) in the BOND-MAX system (Leica Biosystems)
on 4-mm–thick sections. Primary antibodies, dilutions, and scor-
ing evaluation are available upon request.
DNA mismatch repair machinery deficient tumors (MMRd)
were defined in the absence of nuclear immunostaining for one of
the couples MLH1/PMS2 or MSH2/MSH6 in tumor cells (12).
Consensus molecular subgroups (CMS) were qualified
according to Ten Hoorn and colleagues (13) by assessing four
IHC markers (FRMD6, ZEB1, HTR2B, CDX2) in combination
Translational Relevance
This study focused on two rare and distinct subgroups
of non-V600EBRAF-mutated metastatic colorectal cancer
patients while comparing them with V600EBRAF-mutated
and a control set of wild-type patients. A detailed
description of clinical and pathologic features, including
consensus molecular subtypes and BM1/BM2 categoriza-
tion according to Barras and colleagues, is reported
along with outcome data. Results underline the impor-
tance of non-V600EBRAF mutation detection and point out
the need for focusing therapeutic research efforts, taking
into account the specificities of these peculiar colorectal
cancer subtypes.
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with pan-cytokeratin (KER) to normalize results. Primary tumors
and/or metastasis were then categorized into the three CMS
classes (CMS1, CMS2/3, or CMS4) using the online classification
tool (refs. 14, 15; Supplementary Fig. S1).
In BRAF class 2 and 3 cases, histologic type and grading was
revised according to the last updated WHO classification (16).
Cytokeratin expression pattern was evaluated by CK7 and CK20
expression, while tumor-infiltrating lymphocytes by means of
positive intratumoral CD3/CD8 elements. To stratify class 2 and 3
tumors according to Barras and colleagues (7) in BM1 and BM2
groups, an IHCprofiling for CDK1, ATM, Phospho-AKT (Ser473),
Cyclin D1, and Phospho-4E-BP1 (Thr70) expression was per-
formed (Supplementary Fig. S2). According to the Barras' article,
retained expression of ATM, activation of the AKT/4EB-P1 cascade
(considering both the phosphorylated forms of AKT and 4E-BP1),
low CDK1 expression, and high Cyclin D1 expression are BM1
markers. Because no a priori criteria have been defined, we
exploratively categorized each tumor based on their IHC profiles
as follows.
To stratify class 2 and 3 tumors according to Barras and
colleagues in BM1 and BM2 groups, we exploratively categorized
each tumor based on the presence/absence of these five markers:
CDK1, ATM, Phospho-Akt (Ser473), CyclinD1, and Phospho-4E-
BP1 (Thr70). Because BM1 is characterized by activation of PI3K/
mTOR/AKT pathway, while BM2 of cell-cycle pathway, we
assigned samples to BM1 or BM2 based on the coherence of the
following parameters. Overexpression of Phospho-Akt, Phospho-
4E-BP1, ATM, and Cyclin D1, and downregulation of CDK1 were
consistent with a BM1 profile. On the other hand, BM2 cases were
characterized by overexpression of CDK1 and downregulation of
the remainingmarkers. A tumorwas considered positive in ATM if
>10% of tumor cells were positive for nuclear ATM staining. The
activation of the AKT/4E-BP1 cascade was defined in the presence
of high expression levels of the phosphorylated forms of AKT and/
or 4E-BP1. High levels of Cyclin D1 and CDK1 expression were
defined in the presence of at least 50% of positive cancer cells
(Cyclin D1 in the nucleus, CDK1 both in the nucleus and
cytoplasm). Samples with 4 or 5 coherent parameters were
defined as BM1 or BM2, whereas tumors in which three out of
five parameters were coherent with the hypothesis were defined as
borderline BM1or BM2. Tumors with only one or two parameters
coherent with the original classification were defined as not
evaluable.
Statistical analysis
Fisher exact test or x2 test were used when appropriate to
compare clinical, pathologic, and molecular features according
to BRAFmutational status (BRAFwild-type vs. BRAF-mutant class
Table 1. Baseline characteristics and major clinical parametersa
Characteristics
BRAF wt
TOT ¼ 540 N (%)
BRAF mut class 1
TOT ¼ 92 N (%)
BRAF mut class 2
TOT ¼ 12 N (%)
BRAF mut class 3
TOT ¼ 13 N (%) P Pb Pc Pd
Sex Female 200 (37) 45 (49) 6 (50) 6 (46) 0.0458 1.0000 1.0000 1.0000
Male 340 (63) 47 (51) 6 (50) 7 (54)
Age Median (range) 62 (21–91) 69 (35–85) 60 (45–89) 56(45–83) 0.004 0.115 0.759 0.251
Age >70 132 (24) 39 (42) 5 (42) 3 (23) 0.0007 0.4110 1.0000 0.2351
70 408 (76) 53 (58) 7 (58) 10 (77)
Baseline ECOG PS 0 373 (69) 64 (70) 6 (55) 11 (85) 0.8875 0.2506 1.0000 0.167
1 139 (26) 22 (24) 3 (18) 0 (0)
2 28 (5) 6 (6) 3 (27) 2 (15)
Primary tumor resected Yes 314 (58) 75 (82) 9 (75) 10 (77) <0.0001 1.0000 0.6965 0.7097
No 226 (42) 17 (18) 3 (25) 3 (23)
Primary tumor location Right 137 (26) 73 (79) 4 (33.3) 0 (0) <0.0001 0.4666 0.1294 0.0028
Left 265 (49) 14 (15) 4 (33.3) 6 (46)
Rectum 136 (25) 5 (5) 4 (33.3) 7 (54)
NA 2 0 0 0
Presentation of mets Synchronous 383 (71) 60 (65) 7 (58) 7 (54) 0.3401 1.0000 0.7508 0.5395
Metachronous 157 (29) 32 (35) 5 (42) 6 (46)
Mucinous histology Yes 34 (7) 26 (31) 2 (17) 3 (23) <0.0001 1.0000 0.4993 1.0000
No 497 (93) 58 (69) 10 (83) 10 (77)
NA 9 8 0 0
pT 1–2 58 (14) 3 (4) 2 (20) 2 (20) 0.013 1.0000 0.0828 0.0828
3–4 350 (86) 83 (96) 8 (80) 8 (80)
NA 132 6 2 3
pN 0 104 (26) 14 (17) 4 (40) 5 (56) 0.0973 0.6563 0.0944 0.0159
1 292 (74) 70 (83) 6 (60) 4 (44)
NA 144 8 2 4
Metastatic sites, n 1 358 (66) 61 (66) 9 (75) 10 (77) 0.9203 1.0000 0.7467 0.5406
2 182 (34) 31 (34) 3 (25) 3 (23)
aAt the time of first-line treatment start or, for candidates to BSC only, at the first visit for metastatic disease.
bClass 2 versus class 3.
cClass 1 versus class 2.
dClass 1 versus class 3.
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1 vs. BRAF-mutant class 2 vs. BRAF-mutant class 3; BRAF-mutant
class 1 vs. BRAF-mutant class 2; BRAF-mutant class 1 vs. BRAF-
mutant class 3 and BRAF-mutant class 2 vs. BRAF-mutant class 3).
OS was defined as the time from the diagnosis of metastatic
disease to death due to any cause whereas progression-free sur-
vival (PFS) was calculated from the date of first-line systemic
treatment start to the first observed progression or death due
to any cause. OS and PFS analyses were performed according to
the Kaplan–Meier method and survival curves were compared
using the log-rank test. Statistical significance was set at P ¼ 0.05
for a bilateral test. All analyses were carried out by means of
MedCalc Software.
Results
Patients' characteristics, clinical outcome, and treatments
Class 1, 2, and 3 BRAF mutated included 92, 12, and 13
patients, respectively. BRAF wild-type patients were 540. Female
patients were 49%, 50%, 46%, and 37% in the 4 groups, respec-
tively.Median agewas 69, 60, 56, and 62 years (P¼ 0.004). Right-
sided primary tumor occurred in 79%, 33.3%, 0%, and 26% of
cases (P < 0.001; Table 1).
Class 3 BRAF-mutated patients were more frequently left-sided
(46% vs. 15%, P ¼ 0.003), with no locoregional nodal involve-
ment (56% vs. 17%, P¼ 0.016) and no peritoneal spread (100%
vs. 69%, P ¼ 0.018) compared with class 1 ones. No differences
were observed comparing class 2 with class 1 or class 3 cases
(Tables 1 and 2).
Median OS was 21.0 versus 23.4 versus 44.5 versus 42.2
months, in BRAF-mutated class 1, 2, 3, and BRAF wild-type,
respectively (P < 0.0001). Hazard ratio (HR) for OS was 2.38
(95%CI1.61–3.54) for class 1BRAFmutated, 1.90 (95%CI 0.85–
4.26) for class 2 BRAFmutated, and 0.93 (95% CI 0.51–1.69) for
class 3 BRAF mutated compared with BRAF wild-type patients
(Fig. 1).
Median PFS from the beginning of the first-line treatment
was 7.3 versus 7.0 versus 13.8 versus 10.1 months, in the four
groups, respectively (P < 0.0001). HR for PFS was 2.02 (95% CI,
Table 2. Sites of metastasis at diagnosis
Sites of mets at diagnosis
BRAF wt
TOT ¼ 540 N (%)
BRAF mut class 1
TOT ¼ 92 N (%)
BRAF mut class 2
TOT ¼ 12 N (%)
BRAF mut class 3
TOT ¼ 13 N (%) P Pa Pb Pc
Liver Yes 387 (72) 44 (48) 8 (67) 10 (77) <0.0001 0.6728 0.3579 0.0740
No 153 (28) 48 (52) 4 (33) 3 (23)
Lung Yes 104 (19) 15 (16) 2 (18) 2 (15) 0.6101 1.0000 1.0000 1.0000
No 436 (81) 77 (84) 10 (82) 11 (85)
Distant nodes Yes 109 (20) 38 (41) 2 (18) 2 (15) <0.0001 1.0000 0.1234 0.1245
No 431 (80) 54 (59) 10 (82) 11 (85)
Peritoneum Yes 102 (19) 29 (31) 3 (27) 0 (0) 0.0098 0.0957 0.7510 0.0176
No 438 (81) 63 (69) 9 (73) 13 (100)
Other Yes 60 (11) 12 (13) 1 (10) 3 (23) 0.729 0.5930 1.0000 0.3928
No 480 (89) 80 (87) 11 (90) 10 (77)
aClass 2 versus class 3.
bClass 1 versus class 2.
cClass 1 versus class 3.
Figure 1.
Median OS according to BRAF
mutation classes.
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1.39–2.94) for class 1 BRAFmutated, 2.49 (95% CI, 0.92–6.74)
for class 2 BRAF mutated, and 0.85 (95% CI, 0.47–1.54) for
class 3 BRAF mutated compared with BRAF wild-type patients
(Fig. 2).
In the group of BRAF wild-type patients, among 463 patients
undergoing first-line chemotherapy, 49 received a monotherapy
plus/minus a biologic agent, 288 received a doublet plus/minus a
biologic agent, 124 received a three drugs combination plus/
minus a biologic agent, and 2 received other treatments. Overall,
292 of them received a bevacizumab-based treatment and 123 an
anti-EGFR antibody.
Among 73 class 1 BRAF-mutated patients receiving first-line
treatment, 7 underwent a monotherapy plus/minus a biologic
agent, 43 received a doublet plus/minus a biologic agent, 14
received a three drugs combination plus/minus a biologic agent,
and 9 received other treatments. Overall, 50 of them received a
bevacizumab-based treatment and 7 received a treatment with an
anti-EGFR antibody.
Nine of 12 class 2 BRAF-mutated patients received a first-line
treatment. In particular, 2 underwent a monotherapy and 7 a
doublet plus/minus a biologic agent. None of them received an
anti-EGFR antibody.
Nine of 13 class 3 BRAF-mutated patients received a first-line
treatment. In particular, 1 underwent a monotherapy, 5 a
doublet plus/minus a biologic agent, 3 a three drugs combination
plus/minus a biologic agent. Overall, 4 of them received a
bevacizumab-based treatment and 5 received treatment with an
anti-EGFR antibody.
Mutational status and CMS in BRAF-mutant patients
Among class 1 BRAF-mutated patients, adequate tissue speci-
mens were available for 74 of 92 patients. In 40 of 74 cases, both
primary and metastatic samples were available (9 cases had
multiple metastatic sites available for IHC analysis). Overall, as
indicated in Table 3, 39% of class 1 tumors were defined as
CMS1 (immune-like subtype), 44% of patients as CMS 2–3
(epithelial-like subtype), and 17% of patients as CMS4 (mesen-
chymal-like subtype). Three cases were deemed as not evaluable
due to lack of concordance between primary and metastatic
samples.
Among class 2 BRAF-mutated patients, all tumors carried
a BRAF p.K601E mutation. Of note, one tumor was character-
ized by a concomitant NRAS p.G12C mutation. Adequate
tissue specimens were available for 11 of 12 patients. A total
of 20 specimens were considered (8 primary and 12 metastat-
ic); three cases had multiple metastatic sites available for
IHC analysis and in three cases both primary and metastatic
samples were available. All analyzed samples were categorized
as CMS 2–3.
Among class 3 BRAF-mutated patients, 2 tumors carried a BRAF
p.D594N mutation and 11 a BRAF p.D594G mutation. No other
concomitant RAS mutation was identified. Adequate tissue
Figure 2.
Median PFS according to BRAF
mutation classes.
Table 3. Molecular stratification according to CMS
BRAF mut class 1
TOT ¼ 74 N (%)
BRAF mut class 2
TOT ¼ 11 N (%)
BRAF mut class 3
TOT ¼ 10 N (%) P Pa Pb Pc
CMS 1 - Immune-like 28 (39%) 0 (0%) 0 (0%)
CMS 2/3 - Epithelial-like 31 (44%) 11 (100%) 10 (100%)
0.0146 1 0.0015 0.0009
CMS 4 - Mesenchymal-like 12 (17%) 0 (0%) 0 (0%)
NA 3 0 0
aClass 2 versus class 3.
bClass 1 versus class 2.
cClass 1 versus class 3.
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specimenswere available for 10of 13patients.Overall 18 samples
were analyzed (8 primary and 10metastatic); 3 cases hadmultiple
metastatic sites available for IHC analysis and in 3 cases both
primary and metastatic samples were available. All analyzed
samples were categorized as CMS 2–3.
Pathologic features, lymphocyte infiltration, and BM1/BM2
classification in class 2 and 3 BRAF-mutated patients
On the basis of the WHO classification, among class 2 BRAF-
mutated cases, 1 tumor had mucinous histology, 1 micropa-
pillary histology, and 9 were not otherwise specified (NOS)
adenocarcinomas. Tumor grade was high (i.e. grade 3 and 4)
in 5 cases and low (i.e., grade 1 and 2) in the remaining
six tumors. Intratumor phenotypic heterogeneity was evident
only in a NOS adenocarcinoma, which showed intermingled
areas of well-to-poor differentiation. No MMRd tumor was
identified (Table 3). All cases showed a high CDX2 expression.
In one case, metastatic samples showed a significant loss of
CDX2 expression in comparison with the matched primary
tumor; however, those metastatic lesions retained the same
histologic grade and a strong CK20 positivity, as observed in
primary samples. The analysis of cytokeratins expression and
infiltrating lymphocytes evaluation was possible in 9 samples.
Two tumors (29%) were characterized by a low CK20 expres-
sion and two metastatic samples showed a significant loss in
CK20 expression in comparison with their matched primary/
metastatic samples. All samples showed loss/low CK7 expres-
sion, in particular, 3 cases (33.3%) showed a faint (1þ) CK7
immunoreactivity. Median CD3- and CD8-positive infiltrating
lymphocytes per high power field were high in 4 cases (Table 4;
Supplementary Fig. S3).
Among class 3 BRAF-mutated patients, based on the WHO
classification, 2 tumors had micropapillary histology, 1 cribri-
form histology, and 7 were NOS adenocarcinomas. Intratumor
phenotypic heterogeneity was evident in the 2 cases with
micropapillary histology, which showed areas of poorly differ-
entiated NOS histology. Tumor grade was high in 3 tumors and
low in the remaining 7. As observed in class 2 lesions, no
MMRd tumor was identified. Three cases (30%) showed a low
expression of CDX2. Four tumors (40%) showed a low CK20
expression, all samples showed loss/low CK7 expression,
whereas 2 samples showed a faint CK7 immunoreactivity. No
significant intratumor heterogeneity for CMS, CDX2, and cyto-
keratins expression was observed in the 3 cases with multiple
metastatic biopsies, nor among matched primary and meta-
static samples. Median CD3- and CD8-positive infiltrating
lymphocytes per high-power field were low in all cases (Table 4;
Supplementary Fig. S3).
Overall no differenceswere observed among class 2 and 3 cases,
with the exception of a higher median CD3- and CD8-positive
lymphocytes infiltration in class 2 BRAF-mutated samples
(P ¼ 0.033; Table 4).
In class 2 BRAF-mutated tumors, 6 cases were positive for
ATM, 7 showed an activation in AKT/4E-BP1, 2 were charac-
terized by high levels of CDK1, and 3 by high levels of Cyclin
D1. Overall, 5 cases were classified as BM1 (56%), 4 as BM2
(44%), whereas 2 tumors were not classifiable according to BM
status (Table 4).
In class 3 BRAF-mutated tumors, 4 cases were positive for ATM,
5 showed an activation in AKT/4E-BP1, 5 were characterized by
high levels of CDK1, and 5 by high levels of Cyclin D1. Overall,
2 cases were classified as BM1 (33%), 4 as BM2 (67%), whereas
4 tumors were not classifiable according to BM status (Table 4).
Discussion
Several clinical and pathologic descriptions of class 1 BRAF-
mutated mCRC patients (i.e. V600E) have been published indi-
cating specific features and overall poor life expectancy (5, 6). Our
work characterized from a clinical, prognostic, and biological
perspective the complete panel of knownBRAFmutations accord-
ing to functional classes, showing specific features for class 2
BRAF-mutated mCRC that have never been so extensively
reported before, mainly due to their rarity. Moreover, we con-
firmed previous findings on class 1 and class 3 BRAF mutat-
ed (8, 10) and cross compared all the categories.
Looking at OS and PFS data, we observed that class 2 BRAF-
mutated patients haveworse prognosis comparedwith class 3 and
wild-type patients, and class 1–class 2 BRAF-mutated patients
share similar poor median OS and PFS.
From a practical point of view, the identification of new
subgroups of patients with mCRC with specific and rare BRAF
mutations underlines the importance of the extensive adoption of
modern techniques such asmass spectrometry orNGS in the daily
clinical assessment of patients with mCRC.
In this study, we applied the CMS classification to the 3
BRAF classes adopting the practical and rapid IHC method
proposed by Trinh and colleagues (15), which allow to
Table 4. Histopathologic features, tumor-infiltrating lymphocyte
immunophenotype, and BM1/BM2 classification in BRAF-mutated class 2 and
3 patients
BRAF mut class 2
TOT ¼ 11 N (%)
BRAF mut class 3
TOT ¼ 10 N (%) P
Grading
Low 6 (54) 7 (70) 0.659
High 5 (46) 3 (30)
CK7
Low (0–1) 9 (100) 10 (100) 1
High (2–3) 0 (0) 0 (0)
NE 2 0
CK20
Low (0–1) 2 (29) 4 (40) 1




Low (0–150) 0 (0) 3 (30) 0.211




Low (0–20) 5 (56) 10 (100) 0.033
High (>20) 4 (44) 0 (0)
NE 2 0
BM1/BM2 Classification
BM1 5 (56) 2 (33) 0.608
BM2 4 (44) 4 (67)
NA 2 4
Abbreviations: NE, not evaluable; NA, not assessable.
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distinguish CMS2-3 from CMS4 cases, analyzing four specific
markers (CDX2, FRMD6, HTR2B, and ZEB1). We defined CMS1
on the basis of MMRd status, testing for lack of expression of
PMS2 and/or MSH6. All class 2 and 3 patients were classified as
CMS2-3 and no heterogeneity was observed when pairing
primary and/or metastatic samples. So that, disease develop-
ment and progression might not be dependent on immune
related mechanisms and/or mesenchymal-related pathways.
Looking at class 1 BRAF-mutated patients, a wider heteroge-
neity has been detected since CMS1, 2, 3, and 4 occurred,
respectively in 39%, 44%, and 17% of cases. Among this group,
such classification might provide further helpful information
for patients' stratification and treatment decision making and
would need specific studies. Recently Sveen and colleagues (17),
investigated drug sensitivity according to CMS classification in
preclinical models showing that CMS2 cell lines and PDX are
more sensitive to EGFR and HER2 inhibition compared with
other CMS subgroups. Unfortunately, IHC evaluation of CMS
does not allow distinguishing CMS2 and 3 patients, so that to
this extent further studies are needed.
To better characterize differences among class 2 and 3 patients,
we performed a deep IHC characterization. CK7 and CK20 pro-
filing revealed low rate of heterogeneitywhen looking at primaries
and paired metastases and none of our cases showed a complete
inversion of the CK7 and CK20 expression, already described
elsewhere in some class 1 BRAF-mutated cases (18, 19).
Loss of CDX2 expression has been proposed as a negative
prognostic feature in patients with mCRC and it is frequently
associated with V600EBRAF mutation and MMRd (18–20). In
our series, loss of CDX2 was observed among three class 3
BRAF-mutated cases. Because of the small numbers, we were not
able to further speculate on the prognostic impact of such feature.
Of note, CD3 and CD8 infiltration, already known as a prog-
nostic feature in colorectal cancer (21–23), was higher in class 2
BRAF-mutated compared with class 3 patients (P ¼ 0.033). Such
finding might contribute to explain the outcome differences
observed in our series.
From a therapeutic point of view, we cannot drive any
definitive conclusion on anti-EGFR sensitivity of BRAF class
2 and 3 patients. A recent case report described a class 2 BRAF-
mutated mCRC patient achieving a durable response after
treatment with panitumumab single agent (24). In our series,
among class 2 BRAF mutated, only 3 patients received an anti-
EGFR with one responder, among class 3 BRAF mutated 6
patients received an anti-EGFR with 4 responders. Although
definitive conclusions cannot be drawn, taking into account the
kinase signaling mechanisms in class 2 and 3 patients, it could
be hypothesized that class 3 patients might derive some benefit
from anti-EGFRs due to their impaired kinase activity and to
their RAS dependency. On the other hand, no reliable and
specific data are available regarding systemic treatments of class
2 and 3 BRAF-mutated patients.
International guidelines recommend as first-line treatment for
BRAF class 1 patients with good performance status and younger
than 75 years a 4-drug combination (the triplet FOLFOXIRI plus
bevacizumab regimen; ref. 1). Many trials have been performed
and/or are ongoing to identify targeted strategies able to block the
hyperactivated V600EBRAF signals. Disappointing results have
been obtained with BRAF inhibitors alone (24–26) and currently,
new therapeutic options are under evaluation for this subgroup of
patients adopting BRAF plus MEK inhibitors together with anti-
EGFRmAbs (27). The recent stratificationof class 1BRAF-mutated
patients into BM1 and BM2 upon gene expression laid the basis
for a more tailored biologic approach in the development of
targeted therapies. Specifically, BM1 subgroup is characterized by
activation of KRAS/mTOR/AKT/4EBP1 pathway, whereas the
BM2 had a deregulation in the cell cycle (7). In our study, we
assigned samples to BM1 or BM2 category adopting a specific IHC
expression analyses. Of note, 2 and 4 cases among class 2 and 3
patients, respectively, were not assigned to either BM1 or BM2
because they presented a peculiar IHCprofile not properlymatch-
ing with BM1/BM2 categorization. One can hypothesize the
presence of peculiar activation pathways for non-V600EBRAF-mutat-
ed cases, however, we should also consider the intrinsic limita-
tions of our results due to the application of a different technique
(IHC instead of gene expression) and the limited sample size of
our work.
Interestingly, in vitro sensitivity of class 2 and 3 BRAFmutations
toMEK andBRAF inhibition has been proven inmelanoma, and a
small number of patients with thesemutations showed responses
to treatment with MEK inhibitors (28–31). The largest cohort of
patients was collected by Boweyer and colleagues describing the
antitumor activity of trametinib in 5 patients bearing the rare class
2 or class 3 BRAF mutations (32). Moreover, to elucidate these
differences, functional studies were conducted in melanoma
models showing that the activation of RAS and ERK pathways
by these three classes through different mechanisms can explain
their different sensitivity to therapeutic inhibitors: class 1 is
sensitive to RAF "monomer" inhibitors (i.e. vemurafenib), class
2 is resistant to vemurafenib and could be sensitive to novel RAS
dimer inhibitors (i.e. LY3009120) or MEK inhibitors (i.e. trame-
tinib), class 3 is potentially sensitive to RTKs inhibitors (i.e.,
dasatinib; refs. 3, 5, 9, 11). Further studies are needed to clarify
such mechanisms in colorectal cancer models and patients in the
next future.
In conclusion, our study extensively described for the first
time the non-V600EBRAF mutations as two different subtypes of
rare mCRC with specific clinical and prognostic and pathologic
features that might be taken into account when planning new
basic research initiatives and innovative clinical trials in this
setting.
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